Biotronik has received CE approval for two new uses of the Orsiro Mission drug-eluting stent: (1) 1-month DAPT in high bleeding risk (HBR) patients, and (2) treatment of moderately to severely calcified lesions.

The stent now also offers enhanced features, including an ultrathin strut design for improved vascular compatibility and post-dilation capability up to 5.0 mm in selected sizes. These updates support safer, more personalized treatment—especially for complex or high-risk coronary cases.